{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:16:33Z","timestamp":1783617393719,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project","award":["2025ZD01905200"],"award-info":[{"award-number":["2025ZD01905200"]}]},{"name":"Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project","award":["2025ZD01905205"],"award-info":[{"award-number":["2025ZD01905205"]}]},{"name":"the Eastern Talent Plan Youth Project 2024"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360391"],"award-info":[{"award-number":["82360391"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenzhen Science and Technology Program","award":["JCYJ20220530163212029"],"award-info":[{"award-number":["JCYJ20220530163212029"]}]},{"name":"Liuzhou Science and Technology program","award":["2020NBAD0801"],"award-info":[{"award-number":["2020NBAD0801"]}]},{"DOI":"10.13039\/100022957","name":"Double Thousand Plan of Jiangxi Province","doi-asserted-by":"publisher","award":["jxsq2023201034"],"award-info":[{"award-number":["jxsq2023201034"]}],"id":[{"id":"10.13039\/100022957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40121-026-01385-6","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:43:16Z","timestamp":1781887396000},"page":"2167-2180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Multicenter Study on the Effectiveness of Dolutegravir Plus Lamivudine in Treatment-Naive People Living with HIV with Baseline HIV-1 RNA\u2009&gt;\u2009500,000 Copies\/mL"],"prefix":"10.1007","volume":"15","author":[{"given":"Bichen","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuyun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baofang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-4875","authenticated-orcid":false,"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"19","key":"1385_CR1","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"SL Walmsley","year":"2013","unstructured":"Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1215541.","journal-title":"N Engl J Med"},{"issue":"3","key":"1385_CR2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/jac\/dky467","volume":"74","author":"V Joly","year":"2019","unstructured":"Joly V, Burdet C, Landman R, et al. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). J Antimicrob Chemother. 2019;74(3):739\u201345. https:\/\/doi.org\/10.1093\/jac\/dky467.","journal-title":"J Antimicrob Chemother"},{"key":"1385_CR3","doi-asserted-by":"publisher","unstructured":"Acquired Immunodeficiency Syndrome Professional Group, Society of Infectious Diseases, Chinese Medical Association; Chinese Center for Disease Control and Prevention. Chinese guidelines for the diagnosis and treatment of human immunodeficiency virus infection\/acquired immunodeficiency syndrome (2024 edition). Chin Med J (Engl). 2024;137(22):2654\u201380. https:\/\/doi.org\/10.1097\/CM9.0000000000003383.","DOI":"10.1097\/CM9.0000000000003383"},{"key":"1385_CR4","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240031593. Accessed 10 Oct 2025."},{"issue":"1","key":"1385_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","volume":"43","author":"L Men\u00e9ndez-Arias","year":"2022","unstructured":"Men\u00e9ndez-Arias L, Delgado R. Update and latest advances in antiretroviral therapy. Trends Pharmacol Sci. 2022;43(1):16\u201329. https:\/\/doi.org\/10.1016\/j.tips.2021.10.004.","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"1385_CR6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"JM Llibre","year":"2023","unstructured":"Llibre JM, Brites C, Cheng CY, et al. Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week\u00a048 results from the phase\u00a03, noninferiority SALSA randomized trial. Clin Infect Dis. 2023;76(4):720\u20139. https:\/\/doi.org\/10.1093\/cid\/ciac130.","journal-title":"Clin Infect Dis"},{"issue":"10167","key":"1385_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/s0140-6736(18)32462-0","volume":"393","author":"P Cahn","year":"2019","unstructured":"Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week\u00a048 results from two multicentre, double-blind, randomised, non-inferiority, phase\u00a03 trials. Lancet. 2019;393(10167):143\u201355. https:\/\/doi.org\/10.1016\/s0140-6736(18)32462-0.","journal-title":"Lancet"},{"key":"1385_CR8","doi-asserted-by":"publisher","unstructured":"Wei Y, Li J, Xu R, et al. Efficacy and safety profiles of dolutegravir plus lamivudine vs. bictegravir\/emtricitabine\/tenofovir alafenamide in therapy-na\u00efve adults with HIV-1. Chin Med J (Engl). 2023;136(22):2677\u201385. https:\/\/doi.org\/10.1097\/cm9.0000000000002907.","DOI":"10.1097\/cm9.0000000000002907"},{"issue":"7","key":"1385_CR9","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3851\/imp2531","volume":"18","author":"MM Santoro","year":"2013","unstructured":"Santoro MM, Armenia D, Alteri C, et al. Impact of pre-therapy viral load on virological response to modern first-line HAART. Antivir Ther. 2013;18(7):867\u201376. https:\/\/doi.org\/10.3851\/imp2531.","journal-title":"Antivir Ther"},{"issue":"1","key":"1385_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40249-020-00700-8","volume":"9","author":"S Chen","year":"2020","unstructured":"Chen S, Han Y, Song XJ, et al. Very high baseline HIV viremia impairs efficacy of non-nucleoside reverse transcriptase inhibitor-based ART: a long-term observation in treatment-na\u00efve patients. Infect Dis Poverty. 2020;9(1):75. https:\/\/doi.org\/10.1186\/s40249-020-00700-8.","journal-title":"Infect Dis Poverty"},{"issue":"14","key":"1385_CR11","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1097\/00002030-200109280-00012","volume":"15","author":"JE Kaplan","year":"2001","unstructured":"Kaplan JE, Hanson DL, Jones JL, Dworkin MS. Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents. AIDS. 2001;15(14):1831\u20136. https:\/\/doi.org\/10.1097\/00002030-200109280-00012.","journal-title":"AIDS"},{"issue":"6","key":"1385_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1172\/jci9079","volume":"105","author":"GP Rizzardi","year":"2000","unstructured":"Rizzardi GP, De Boer RJ, Hoover S, et al. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. J Clin Invest. 2000;105(6):777\u201382. https:\/\/doi.org\/10.1172\/jci9079.","journal-title":"J Clin Invest"},{"issue":"11","key":"1385_CR13","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1080\/14787210.2022.2128766","volume":"20","author":"X Yang","year":"2022","unstructured":"Yang X, Fu Y, Xie X, et al. Real-world implementation of dolutegravir plus lamivudine in people living with HIV in Southwest China. Expert Rev Anti Infect Ther. 2022;20(11):1501\u20138. https:\/\/doi.org\/10.1080\/14787210.2022.2128766.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"4","key":"1385_CR14","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40121-024-00950-1","volume":"13","author":"P Benson","year":"2024","unstructured":"Benson P, Kuretski J, Donovan C, et al. Real-world effectiveness of dolutegravir\/lamivudine in people with HIV-1 in test-and-treat settings or with high baseline viral loads: TANDEM study subgroup analyses. Infect Dis Ther. 2024;13(4):875\u201389. https:\/\/doi.org\/10.1007\/s40121-024-00950-1.","journal-title":"Infect Dis Ther"},{"issue":"7","key":"1385_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jama.2024.24543","volume":"333","author":"RT Gandhi","year":"2025","unstructured":"Gandhi RT, Landovitz RJ, Sax PE, et al. Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA panel. JAMA. 2025;333(7):609\u201328. https:\/\/doi.org\/10.1001\/jama.2024.24543.","journal-title":"JAMA"},{"key":"1385_CR16","unstructured":"US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv. Accessed 10 Oct 2025."},{"issue":"1","key":"1385_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.20411\/pai.v5i1.341","volume":"5","author":"A Muscatello","year":"2020","unstructured":"Muscatello A, Nozza S, Fabbiani M, et al. Enhanced immunological recovery with early start of antiretroviral therapy during acute or early HIV infection-results of Italian network of ACuTe HIV InfectiON (INACTION) retrospective study. Pathog Immun. 2020;5(1):8\u201333. https:\/\/doi.org\/10.20411\/pai.v5i1.341.","journal-title":"Pathog Immun"},{"key":"1385_CR18","doi-asserted-by":"publisher","unstructured":"Rolle CP, Berhe M, Singh T, et al. Sustained virologic suppression with dolutegravir\/lamivudine in a test-and-treat setting through 48\u00a0weeks. Open Forum Infect Dis. 2023;10(3):ofad101. https:\/\/doi.org\/10.1093\/ofid\/ofad101.","DOI":"10.1093\/ofid\/ofad101"},{"issue":"S1","key":"1385_CR19","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1097\/qai.0000000000003053","volume":"91","author":"F Zhao","year":"2022","unstructured":"Zhao F, Rao M, Chen W, et al. Dolutegravir plus lamivudine dual-drug regimen in treatment-naive HIV-1-infected patients with high-level viral load: preliminary data from the real world. J Acquir Immune Defic Syndr. 2022;91(S1):S16\u20139. https:\/\/doi.org\/10.1097\/qai.0000000000003053.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"1385_CR20","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1186\/s12879-024-09624-2","volume":"24","author":"Y Dou","year":"2024","unstructured":"Dou Y, Liao G, Lu R, et al. DTG + 3TC dual therapy for the treatment na\u00efve patients with viral load exceeding 500,000\u00a0copies\/mL: a retrospective study. BMC Infect Dis. 2024;24(1):720. https:\/\/doi.org\/10.1186\/s12879-024-09624-2.","journal-title":"BMC Infect Dis"},{"key":"1385_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.108321","volume":"164","author":"CJ Yang","year":"2026","unstructured":"Yang CJ, Li L, Zhao Q, et al. Dolutegravir\/lamivudine versus bictegravir\/emtricitabine\/tenofovir alafenamide fumarate: real-world assessment of effectiveness and weight Gain in na\u00efve people living with HIV of Asian OrigiN (DRAGON). Int J Infect Dis. 2026;164:108321. https:\/\/doi.org\/10.1016\/j.ijid.2025.108321.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"1385_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.24875\/AIDSRev.24000004","volume":"26","author":"PRS Almeida","year":"2024","unstructured":"Almeida PRS, Rafael CAC, Pimentel V, Abecasis AB, Sebasti\u00e3o CS, Morais J. Adherence to antiretroviral therapy among HIV-1 patients from sub-Saharan Africa: a systematic review. AIDS Rev. 2024;26(3):102\u201310. https:\/\/doi.org\/10.24875\/AIDSRev.24000004.","journal-title":"AIDS Rev"},{"issue":"12","key":"1385_CR23","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1097\/QAD.0000000000002979","volume":"35","author":"CP Rolle","year":"2021","unstructured":"Rolle CP, Berhe M, Singh T, et al. Dolutegravir\/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV. AIDS. 2021;35(12):1957\u201365. https:\/\/doi.org\/10.1097\/QAD.0000000000002979.","journal-title":"AIDS"},{"issue":"3","key":"1385_CR24","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/cid\/ciaf159","volume":"81","author":"J Hao","year":"2025","unstructured":"Hao J, Liu X, Wang D, et al. Transmitted HIV-1 drug resistance among newly diagnosed individuals in 31 provincial-level administrative divisions in china in 2023: a cross-sectional survey. Clin Infect Dis. 2025;81(3):531\u20138. https:\/\/doi.org\/10.1093\/cid\/ciaf159.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1385_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00126334-200112010-00002","volume":"28","author":"G Skowron","year":"2001","unstructured":"Skowron G, Street JC, Obee EM. Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28(4):313\u20139. https:\/\/doi.org\/10.1097\/00126334-200112010-00002.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"1385_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s13104-025-07428-4","volume":"18","author":"NS Muhie","year":"2025","unstructured":"Muhie NS, Tegegne AS. CD4 cell count and viral load count association and its joint risk factors among adult TB\/HIV co-infected patients: a retrospective follow-up study. BMC Res Notes. 2025;18(1):377. https:\/\/doi.org\/10.1186\/s13104-025-07428-4.","journal-title":"BMC Res Notes"},{"issue":"2","key":"1385_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11904-022-00600-6","volume":"19","author":"CE Diggins","year":"2022","unstructured":"Diggins CE, Russo SC, Lo J. Metabolic consequences of antiretroviral therapy. Curr HIV\/AIDS Rep. 2022;19(2):141\u201353. https:\/\/doi.org\/10.1007\/s11904-022-00600-6.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"3","key":"1385_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/QAD.0b013e32835b2ef1","volume":"27","author":"A Monforte","year":"2013","unstructured":"Monforte A, Reiss P, Ryom L, Monforte AD, et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS. 2013;27(3):407\u201315. https:\/\/doi.org\/10.1097\/QAD.0b013e32835b2ef1.","journal-title":"AIDS"},{"issue":"11","key":"1385_CR29","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/s1473-3099(13)70271-8","volume":"13","author":"JE Lake","year":"2013","unstructured":"Lake JE, Currier JS. Metabolic disease in HIV infection. Lancet Infect Dis. 2013;13(11):964\u201375. https:\/\/doi.org\/10.1016\/s1473-3099(13)70271-8.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"1385_CR30","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s11904-016-0321-0","volume":"13","author":"NT Funderburg","year":"2016","unstructured":"Funderburg NT, Mehta NN. Lipid abnormalities and inflammation in HIV inflection. Curr HIV\/AIDS Rep. 2016;13(4):218\u201325. https:\/\/doi.org\/10.1007\/s11904-016-0321-0.","journal-title":"Curr HIV\/AIDS Rep"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01385-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01385-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01385-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:06:19Z","timestamp":1783616779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01385-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1385"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01385-6","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bichen Xue, Rui Jiang, Yanyun Dou, Jinglan Lai, Wei Zou, Yingjie Fang, Weiguang Feng, Fuyan Sun, Chunhui Yan, Tao Guo, Jian Ao, Ke Hong, Yuhong Xiong, Qi Chen, Chunhua Xu, Guangyong Xu, Xiaoshui Lu, Yuanyuan He, Yirong Shi, Xiaoyan Yang, Yahong Chen, Jiuyun Luo, Baofang Yang, Yanhua Fu, Fang Zhao, Jin Li, and Jun Chen declare that they have no competing interests. Jun Chen is an Editorial Board member of\n                      Infectious Diseases and Therapy\n                      , but was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study protocol was approved by the\u00a0Shanghai\u00a0Public\u00a0Health\u00a0Clinical\u00a0Center\u00a0Ethics Committee (approval number 2023-S084-01), and was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Signed informed consent was obtained from participants for prospective enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}